Keratoacanthoma of the lip: Activation of the mTOR pathway, tumor suppressor proteins, and tumor senescence

Medicine (United States)

Volumn 94, Issue 38, 2015, Pages

  Dillenburg, Caroline Siviero ^a,b   Martins, Manoela Domingues ^a,b   Meurer, Luise ^c   Castilho, Rogerio Moraes ^a   Squarize, Cristiane Helena ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b School of Dentistry   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6; TUMOR SUPPRESSOR PROTEIN; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; AGING; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; DYSKERATOSIS; ELASTOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KERATOACANTHOMA; LIP TUMOR; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL AGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; CELL AGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; LIP NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASE; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84942546620     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001552     Document Type: Article

References (63)

1. Wagner VP, Martins MD, Dillenburg CS, et al. Histogenesis of keratoacanthoma: histochemical and immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:310-317.
2. Savage JA, Maize JC. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014;36:422-429.
3. LeBroit P, Burg G, Weedon D, et al. Pathology and Genetics of Tumours of the Skin. 3rd ed. Lyon: IARC Press; 2006.
4. Ko CJ, McNiff JM, Bosenberg M, et al. Keratoacanthoma: clinical and histopathologic features of regression. J Am Acad Dermatol. 2012;67:1008-1012.
5. Weedon D. Keratoacanthoma: a personal perspective. Curr Diagn Pathol. 2003;9:259-265.
6. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatol Basel Switz. 1999;199:208-212.
7. Goldsmith L, Katz S, Gilchrest B, et al. Fitzpatrick's Dermatology in General Medicine, Eighth Edition, 2 Volume Set. Vol 8 edition. New York: McGraw-Hill Professional; 2012.
8. Sánchez Yus E, Simón P, Requena L, et al. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant. Am J Dermatopathol. 2000;22:305-310.
9. Misago N, Takai T, Murata Y, et al. Cases with a spontaneous regression of an infiltrating non-crateriform keratoacanthoma and squamous cell carcinoma with a keratoacanthoma-like component. J Dermatol. 2014;41:430-434.
10. Misago N, Takai T, Toda S, et al. The histopathologic changes in keratoacanthoma depend on its stage. J Cutan Pathol. 2014;7:617-619.
11. Clausen OPF, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol. 2002;119:1367-1372.
12. Li J, Wang K, Gao F, et al. Array comparative genomic hybridization of keratoacanthomas and squamous cell carcinomas: different patterns of genetic aberrations suggest two distinct entities. J Invest Dermatol. 2012;132:2060-2066.
13. Blessing K, Al Nafussi A, Gordon PM. The regressing keratoacanthoma. Histopathology. 1994;24:381-384.
14. Magalhães RF, Cruvinel GT, Cintra GF, et al. Diagnosis and followup of keratoacanthoma-like lesions: clinical-histologic study of 43 cases. J Cutan Med Surg. 2008;12:163-173.
15. Scola N, Segert HM, Stücker M, et al. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma. Clin Exp Dermatol. 2014;39:216-218.
16. Kambayashi Y, Fujimura T, Aiba S. Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma. Acta Derm Venereol. 2013;93:663-668.
17. Jacobs MS, Persons DL, Fraga GR. EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study. J Cutan Pathol. 2013;40:447-454.
18. Basta-Juzbasić A, Klenkar S, Jakić-Razumović J, et al. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma. Acta Dermatovenerol Croat ADC. 2004;12:251-256.
19. Kaabipour E, Haupt HM, Stern JB, et al. Martin A-M. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med. 2006;130:69-73.
20. Omar E. Recurrent facial keratoacanthoma in a patient with diabetes: a case report. BMC Res Notes. 2014;7:257.
21. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947.
22. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362.
23. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606-619.
24. Giudice FS, Squarize CH. The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen. (Suppl 5)2013; pii: 003. doi:10.4172/2157-2518.S5-003.
25. Squarize CH, Castilho RM, Bugge TH, et al. Accelerated wound healing by mTOR activation in genetically defined mouse models. PloS One. 2010;5:e10643d.
26. Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:2558-2568.
27. Squarize CH, Castilho RM, Abrahao AC, et al. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia N Y N. 2013;15:461-471.
28. Tang LH, Gonen M, Hedvat C, et al. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenter-opancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36:1761-1770.
29. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer J Int Cancer. 2012;130:1715-1725.
30. Laplante M. Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293.
31. Oh WJ. Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle Georget Tex. 2011;10:2305-2316.
32. Chen S-J, Nakahara T, Takahara M, et al. Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2. Br J Dermatol. 2009;160:442-445.
33. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: How much is too little? Cancer Res. 2011;71:629-633.
34. Yao D, Alexander CL, Quinn JA, et al. Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAFinduced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci. 2008;121 (Pt 10):1758-1769.
35. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol. 2001;13:748-753.
36. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593-602.
37. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13: 283-296.
38. Chazal M, Marionnet C, Michel L, et al. P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation. Oncogene. 2002;21:2652-2661.
39. Nakamura S, Nishioka K. Enhanced expression of p16 in seborrhoeic keratosis; a lesion of accumulated senescent epidermal cells in G1 arrest. Br J Dermatol. 2003;149:560-565.
40. Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, et al. P16 expression in squamous cell carcinomas of cervix and bladder. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem. 2010;18:344-347.
41. Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG Int J Obstet Gynaecol. 2015;122:64-70.
42. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013;105:1550-1557.
43. Possati-Resende JC, Fregnani JHTG, Kerr LM, et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PloS One. 2015;10:e0134445.
44. Angiero F, Berenzi A, Benetti A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res. 2008;28:2535-2539.
45. Bean SM, Eltoum I, Horton DK, et al. Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. Am J Surg Pathol. 2007;31:555-561.
46. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:4154-4162.
47. Zhao N, Ang M-K, Yin X-Y, et al. Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. Br J Cancer. 2012;107:482-490.
48. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2000;6:1845-1853.
49. Suk JD, Park WS, Kim D-K. Low rates of somatic p53 mutations in keratoacanthomas. J Dermatol Sci. 2009;53:72-73.
50. Hu W, Cook T, Oh CW, et al. Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma. J Am Acad Dermatol. 2000;42:473-475.
51. Ito Y, Kurokawa I, Nishimura K, et al. Keratin and filaggrin expression in keratoacanthoma. J Eur Acad Dermatol Venereol JEADV. 2008;22:353-355.
52. Poligone B, Hayden MS, Chen L, et al. A role for NF-(B activity in skin hyperplasia and the development of keratoacanthomata in mice. PloS One. 2013;8:e71887.
53. Ichikawa E, Ohnishi T, Watanabe S. Expression of keratin and involucrin in keratoacanthoma: an immunohistochemical aid to diagnosis. J Dermatol Sci. 2004;34:115-117.
54. Kuivanen TT, Jeskanen L, Kyllönen L, et al. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol. 2006;19:1203-1212.
55. Manousaridis I, Leverkus M. Malignant epithelial tumors: Part II. Therapy and prevention. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2013;11:9-25quiz 26-27.
56. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
57. Campalani E, Holden CA. Keratoacanthoma associated with the use of topical imiquimod. Clin Exp Dermatol. 2013;38:555-556.
58. Cecchi R, Bartoli L, Brunetti L, et al. Topical imiquimod in the treatment of large facial keratoacanthomas. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2012;147:505-507.
59. LaPresto L, Cranmer L, Morrison L, et al. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil. JAMA Dermatol. 2013;149:279-281.
60. Annest NM, VanBeek MJ, Arpey CJ, et al. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol. 2007;56:989-993.
61. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231-1241.
62. Wen PY, Lee EQ, Reardon DA, et al. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncol. 2012nos117.
63. Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 2008;68:7066-7072.